Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

Executive Summary

• Texas Prostate, led by Dr. James Cochran, performed its 100th TULSA Procedure™ at Dallas Medical Center.
• The transition from private‑pay to a Medicare reimbursement model drove a 500% increase in procedure volume, indicating rapid market adoption.
• Profound’s CEO highlighted the milestone as evidence of expanding access to MRI‑guided, incision‑free prostate therapies across Texas and surrounding states.

Key Details

• Milestone: 100th TULSA Procedure™ completed by Texas Prostate in Dallas Medical Center’s MRI suite.
• Growth Driver: Adoption of a Medicare reimbursement model resulted in a 500% surge in procedure numbers shortly after implementation.
• Geographic Reach: Increased inquiries from throughout Texas and neighboring states; urologists in the Dallas‑Fort Worth Metroplex are seeking training to offer TULSA.
• Technology Highlights: TULSA‑PRO® delivers robotically controlled directional ultrasound via the urethra, heating tissue to 55‑57 °C under continuous MRI thermography, eliminating blood loss, overnight stays, and reducing side‑effects such as incontinence and erectile dysfunction.
• Clinical Applications: Used for prostate cancer and benign prostatic hyperplasia (BPH); capable of whole‑gland, subtotal, hemi, multifocal, and focal treatments.
• Regulatory Status: TULSA‑PRO® cleared/approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE.

Notable Quotes

• “Under this innovative model pioneered by Texas Prostate — bridging private‑pay practices and Medicare‑participating hospitals — Dr. Cochran is demonstrating a way for urologists to accelerate adoption of the next generation of prostate care…” – Arun Menawat, CEO & Chairman, Profound Medical Corp.

Materiality Assessment: Material – Positive (significant commercial traction and reimbursement model shift indicating meaningful revenue growth potential).